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Abstract  
Alternative management strategies for localised prostate cancer are required to reduce morbidity and 
overtreatment. The aim of this study was to evaluate the feasibility, safety and acceptability of exercise training (ET) 
with behavioural support as a primary therapy for low/intermediate risk localised prostate cancer.  
Men with low/intermediate-risk prostate cancer were randomised to 12 months of ET or usual care with physical 
activity advice (UCwA) in a multi-site open label RCT. Feasibility included acceptability, recruitment, retention, 
adherence, adverse events and disease progression. Secondary outcomes included quality of life and cardiovascular 
health indices.  
Of the 50 men randomised to ET (n=25) or UCwA (n=25), 92% (n=46) completed 12 month assessments. Three men 
progressed to invasive therapy (two in UCwA).  In the ET group, men completed mean: 140 mins per week for 12 
months (95% CI 129,152mins) (94% of target dose) at 75% Hrmax. Men in the ET group demonstrated improved 
body mass (mean reduction: 2.0 kg; 95% CI -2.9,-1.1), reduced systolic (mean: 13 mmHg; 95% CI 7,19) and diastolic 
blood pressure (mean:8 mmHg; 95% CI 5,12) and improved quality of life (EQ5D mean:13 points; 95% CI 7,18). There 
were no serious adverse events. 
ET in men with low/intermediate risk prostate cancer is feasible and acceptable with a low progression rate to 
radical treatment. Early signals on clinically relevant markers were found which warrant further investigation. 
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Introduction 
Selecting clinical management strategies for men with localised prostate cancer is a balancing act. The evidence in 
favour of radical treatments such prostatectomy and radiation therapy is disputed, with large randomised studies 
such as PIVOT and ProtecT demonstrating  minimal overall survival advantage.1,2 Nevertheless, living with an 
untreated cancer can be a source of anxiety for men3 and active monitoring is associated with a higher rate of 
disease progression and development of metastatic cancer.1,2 Active surveillance has long been suggested as a 
primary management strategy for localised prostate cancer, particularly in men thought to be at low risk of 
progression, however reliably identifying such men is associated with a degree of uncertainly that men and their 
partners often find difficult to accept,4 particularly as they perceive no active role in such treatment.5  Despite the 
known adverse effects of invasive therapies on quality of life, sexual, urinary and anorectal function6 , many men opt 
out of surveillance in favour of what they perceive as an active management strategy involving conventional or 
investigative ablative therapies.  
 
The benefits of participation in exercise/physical activity and the impact on cancer progression/ mortality outcomes 
has gained much support from observational data sets describing the impact on solid cancers7 and specifically in 
prostate cancer cohorts.8,9 Furthermore, a meta-analysis confirmed exercise interventions improve cancer specific 
outcomes such as disease specific quality of life and physical function as well as reducing fatigue in men with 
prostate cancer.10  Pilot 'lifestyle interventions' have been attempted in localised prostate cancer. However, it is 
important to note these studies focused nearly exclusively on modification of 'lifestyle' to a vegan diet with soy 
supplementation, without data on exercise dose/adherence.11  
 
In tandem, physical activity will reduce risk of other common cancers and associated co-morbidities such as 
cardiovascular disease risk, common in elderly populations.12 Indeed, as demonstrated in the largest RCT thus far 
comparing treatment options, men with localised prostate cancer are nine times more likely to die of other causes 
rather than prostate cancer - CVD mortality being nearly three times more likely.1 Therefore, developing exercise 
training (ET) as a novel primary treatment option for prostate cancer could fundamentally change the way the 
disease  is managed and offer cancer specific and other health advantages for men affected.  The challenge with 
exercise programmes however, is to support men in starting to become physically active and then maintain exercise 
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over the long-term, whilst providing objective data to confirm behaviour change.13 Also, such therapies need to be 
integrated with clinical practice, if they are ever to be considered a realistic treatment option in the health services.  
 
The aim of the Prostate Cancer Novel Therapy (PANTERA) trial was to assess the feasibility and acceptability of 
delivering ET as a novel primary therapy to men with low and intermediate risk localised prostate cancer with a view 
to informing a subsequent definitive trial evaluating the effect on progression to invasive therapy.  
 
Methods 
Study design 
The study was a two-arm open label RCT designed and conducted in line with recent updated CONSORT guidance for 
clinical studies.14 Following regulatory and ethical approvals (UK NHS, HRA) in accordance with the Helsinki 
Declaration, 50 men with localised prostate cancer were recruited via outpatient clinics. All men had histological 
evidence of  low or intermediate risk localised prostate cancer, diagnosed using a combination of clinical, bio-
chemical, imaging and/or biopsy (confirmed within the previous 12 months) and had elected active surveillance as 
an initial management strategy.15  Specifically, only men with Gleason score ≤7 (3+4, not 4+3), up to T2b clinical 
stage tumours, with pre-treatment prostate specific antigen (PSA) ≤20 ng/mL and life expectancy of ≥10 years were 
included. Men with unstable angina, uncontrolled hypertension, recent myocardial infarction (within the past 6 
months), pacemakers or those already undertaking regular physical activity (greater than 90 minutes of moderate 
intensity exercise, per week) or with mental limitation preventing participation in trial assessments were excluded. 
All men were recruited from two hospitals in South Yorkshire (UK) and provided informed consent for study 
participation. 
 
Randomisation and masking  
Randomisation was undertaken using a computer generated algorithm used by cancer prevention trials unit staff at 
Queen Mary University of London, who were independent of the study team.  
 
Procedures 
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Exercise training with behavioural support 
Aerobic ET was undertaken for 12 months, combining supervised and independent elements. All supervised exercise 
sessions were guided by a specialist in clinical exercise science and took place at Sheffield Hallam University or 
community gym facilities involved in the National Centre for Sport and Exercise Medicine network.  Men were set a 
goal of undertaking 150 minutes of exercise per week for 12 months (i.e. 7800 minutes of objectively monitored 
exercise over 12 months). To support this goal, men were asked to attend two group-based supervised exercise 
sessions a week, comprising up to 60 minutes of aerobic exercise. Exercise intensity was set at between 65% to 85% 
of age-predicted maximum heart rate or 12 to 17 on the Borg rating of perceived exertion (RPE) scale,16 in sessions 
of 20-30 minutes of continuous exercise for the first 8 weeks, progressing up to 60 minutes per session thereafter. 
Gym based aerobic ET was conducted using standard ergometers e.g. stationary cycles, rowing ergometers or 
treadmills. In addition, men were required to undertake self-directed exercise sessions per week, using a heart rate 
monitor to objectively record independent exercise behaviour to achieve their 150 minute per week target.  These 
men also recorded their exercise behaviour in log books, which were checked on a regular basis.  
 
The behaviour change support was based on the findings of our Cochrane review of interventions to improve 
exercise behaviour in people living with and beyond cancer.13 We utilised the following behaviour change techniques 
as outlined in the CALO-RE behaviour change taxonomy: setting programme goals; prompting generalisation of 
target behaviour; prompting self-monitoring of behaviour and prompting of practice. Behaviour change counselling 
conducted by the clinical exercise specialist took place bi-monthly, either via face-to-face sessions during exercise or 
via telephone for the first three months and then according to participant preference for the following nine months. 
Ongoing feedback on exercise technique and intensity guidance was provided throughout the supervised sessions as 
appropriate. 
 
Behavioural support was based on Social Cognitive Theory17 (emphasising the importance of self-regulation over 
willpower) and on Habit Theory18 (increases the automaticity of behaviour)  arranging, for example, a regular 
exercise routine with specific times, days and environments to increase the automaticity of physical activity. Decision 
processes regarding whether to engage in exercise would gradually be replaced by the expectation to engage in 
exercise, thereby improving maintenance of behaviour change. The habit element aimed to aid the transition to a 
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more active life and, together with increasing self-regulatory skills, to increase the chance of long-term maintenance. 
Patient perceptions of illness and treatment beliefs were also discussed and addressed with participants using the 
principals of the necessities and concerns frame work.19 For example, discussing beneficial and adverse outcomes 
from participation in active surveillance and undertaking ET as an experimental approach to controlling disease 
progression. Throughout the 12 months, the clinical exercise specialist helped identify and overcome barriers to 
exercise, facilitate self-management strategies, review individual exercise goals and promote self-regulatory skills. 
Please see online appendix 2 for a populated TIDieR checklist. 
 
Usual care with exercise advice 
Men randomised to usual care with advice (UCwA) underwent active surveillance in accordance with the local cancer 
network policy, based on the NICE (CG175) recommendations. All men in this group received the Macmillan “Move 
More” exercise education pack for people living with and beyond cancer (https://be.macmillan.org.uk/be/p-19569-
move-more-guide.aspx ). 
 
Outcome measures 
The primary outcome was feasibility comprising: recruitment; adherence to ET; study retention: acceptability, 
adverse event rate14 and progression to radical treatment during the intervention period. These data were assessed 
by extracting data from screening and recruitment logs, attendance at supervised ET sessions as well as independent 
exercise heart rate recordings, log book records and review of adverse event logs and clinical records. Adverse 
events were classified according to international ethical, scientific and practical standards i.e. Good Clinical Practice 
definitions see (https://www.gov.uk/guidance/good-clinical-practice-for-clinical-trials). 
 
Secondary outcomes were assessed at baseline, 3, 6 and 12 months and included resting heart rate (Polar M400, 
Finland) resting blood pressure and sub-maximal aerobic exercise tolerance assessed by the Bruce treadmill 
(H/P/Cosmos, Germany) protocol,20 body mass and BMI.  Blood pressure measures were taken by the same clinical 
investigator throughout with regularly calibrated automated sphygmomanometer (Dash 2500, GE Healthcare, USA) 
with the average of three recordings taken. Readings were taken in a seated position after the subject had rested for 
a minimum of 10 minutes. Second and third readings were taken 5 minutes later and the mean pressure of the three 
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readings was recorded as the attendance BP.  Quality of life was assessed by the EQ5D questionnaire (see 
https://euroqol.org/). Dietary habits were assessed by the Food frequency questionnaire.21 In addition, we assessed 
the willingness of men to provide one DNA sample for SNP genetic profiling, which could be informative in our 
planned explanatory trial in terms of predicting response to ET. Other secondary outcomes were safety biomarkers 
including PSA and serum androgen profile. A lipid profile (taken fasted) and the metabolic biomarker HbA1c was also 
collected as requested by patients when we consulted them about study design prior to funding. Samples were 
processed at local hospital laboratories and reported on the secure internal National Health Service (NHS) results 
reporting system. Self-reported exercise behaviour was assessed by the Godin Leisure Score index questionnaire22 
self-efficacy by the SCI Self-Efficacy for Exercise Scale23 and exercise habits by the Self-Report Habit Index.23,24  Men 
involved in ET were purposively selected for semi-structured interviews (based on complete vs lower exercise 
adherence) to offer a qualitative perspective on aspects of acceptability of the intervention and participation in the 
trial.  
 
Sample size estimate 
Recruitment target was set at 50 men in 12 months. This target assumed that 200 would be screened, 50% of whom 
would be eligible and 50% of these would agree to participate.  For the purposes of future definitive trial planning, 
the eligibility and participation rates were estimated to within 95% confidence intervals of +/-7% and +/-10% 
respectively. A 75% study completion rate was estimated to within +/-12%, and a 75% intervention completion rate 
to within +/-17%. The sample size of 50 was also considered sufficient for estimating the standard deviation of an 
outcome such as PSA.25 
 
Data analysis 
In accordance with the updated CONSORT guidelines for pilot and feasibility studies 14 (please see CONSORT checklist 
in online appendix 3)  outcomes were assessed using standard descriptive methods for rates and proportions.  
Qualitative methods can be found in online supplement 1.  
 
Results  
Recruitment /retention 
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From June 2015 to June 2016, we screened 160 men with low to intermediate risk prostate cancer from Sheffield 
Teaching Hospitals Trust and Barnsley NHS Trust, of whom 103 were eligible for inclusion. Fifty men were recruited 
and randomised to ET (n=25) or UCwA (n=25) (see Table 1 for baseline characteristics). Thus 64% (95% CI 56%,72%) 
were eligible and 48.5% (95% CI 38.6,58.6) randomised (please see Figure 1 CONSORT diagram).  Retention during 
the trial was excellent, with 46 men completing 12 month assessments (92%). Progression to invasive treatment over 
the 12 month follow-up period was equivalent to that seen in a recent large RCT.1 Overall, three men progressed to 
radical treatment– two in the UCwA and one in the ET arm.  
 
Exercise training adherence 
Adherence in the ET group was excellent with an average of 7304 min (95% CI 6719,7890) completed at 75% Hr max 
(i.e. 94% of target), or 140 min on average per week (95% CI 129,152) over 12 months.  This was broken down as 
3725 min supervised exercise (95% CI 3487,3964) at 77% Hr max (or RPE of 12) and 3579 min of independent 
exercise (95% CI  2911,4247) at 73% Hr max in total over 12 months (please see Figure 2).   
  
Adverse events 
No serious adverse events were reported over the duration of the trial. A total of 64 adverse events were recorded: 
only 8 were related to participation in the ET or study assessments and involved minor chest discomfort, mild joint 
and soft tissue pains and one instance of a nose bleed (pre-existing condition).  
 
Secondary outcomes 
Large, clinically relevant26 effect sizes were seen in the ET group in terms of reduction in diastolic (mean: 8 mmHg; 
95% CI 5,12) and systolic blood pressure (mean: 13 mmHg; 95% CI 7,19) along with substantial improvements in 
submaximal fitness (mean:171 s; 95% CI 124,219), body mass (mean:-2.0 kg; 95% CI -2.9,-1.1), Godin LTI 
questionnaire score (mean:20 points; 95% CI 12,27) and EQ5D questionnaire score (mean:13 points; 95% CI 7,18). An 
increase in UCwA group self-reported exercise behaviour on the Godin questionnaire over the 12 months was also 
observed (mean:15 points; 95% CI 5,25) however this had only a small impact on physiological and fitness outcomes 
such as submaximal fitness, diastolic and systolic blood pressure: please see Table 2. Data from safety biomarkers 
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(PSA, serum testosterone, sex hormone binding globulin, free androgen index) indicates minimal changes in 
biochemical metrics in both groups: please see Table 3.     
 
Over the 12 months follow-up men randomised to ET reported increases in self-efficacy (mean change: 2 points; 95% 
CI 0, 4) and automaticity of behaviour (mean change: 6 points; 95% CI 2, 10). Men randomised to UCwA also 
reported increases in automaticity of behaviour (7 points; 95% CI 2, 12) and self-efficacy (mean change: 1 point; 95% 
CI -2, 4). We asked men to complete food frequency questionnaires at baseline and 12 months, however, the 
feasibility of collecting such data using this tool proved problematic, with only 21 patients returning both baseline 
and 12 month questionnaires. The feasibility of collecting DNA samples for SNP analysis was good with 49/50 men 
agreeing to provide a sample.   Analysis on DNA SNPs will be presented elsewhere.  
 
Acceptability and qualitative data 
Qualitative feedback from men who took part in the ET is presented in four superordinate themes and twelve 
subthemes were identified (Table 4).  These themes are complemented by selected quotes below (see online 
appendix 1 for full details). 
 
 Motivations  
Being diagnosed with prostate cancer and being approached to take part in this trial was an incentive for taking part.  
It was initially discussed with the men that this trial may be of some benefit to their disease and other aspects of 
their health, the men felt that participation would help them achieve these suggested benefits.  
 
 “Well anything that would help you in a desperate situation like having cancer, I mean I appreciate that I’m a 
low risk at the moment. That’s the most, that’s all the motivation I needed really. And then as you get into it you 
realise that it’s therapeutic in all sorts of ways.” (248) 
 
 Adherence 
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The trial demonstrated excellent adherence rates (94%) and the reasons for the men's adherence was discussed in 
great depth.  They reported that supervision and having behaviour change support integrated into the supervision 
was a crucial factor in adherence.  
 
 "I think a combination. It does make you more likely to attend, and also gives you a bit more confidence that 
somebody’s looking over you if you like." (248)  
 
Some of the men had previous experience of other exercise referral schemes such as cardiac rehabilitation, which 
lacked behaviour change support, with the men stating why this trial was different and more engaging than previous 
experiences. 
 
 "Well, yeah, I have to say the whole programme was based around goal setting, because not only did we do 
the exercise in the gym, but we also sat with the specialist from time to time and reviewed our, or set our goals and 
reviewed our progress towards meeting those goals and we talked about rewards and all that kind of thing, which 
never happened on the initial cardio programme." (202) 
 
 The trial 
Practicalities of the trial were discussed.  The majority of the men though the duration and frequency of the trial was 
sufficient, with some stating they would have continued having supervised sessions longer than 12 months due to 
benefit and enjoyment.  The delivery sites were seen as being convenient to men; however, parking was sometimes 
an issue.  
 
 "Actually it all right, it went very quickly. And had it said do another six months or another year I’d have done 
it. Yeah, because I was enjoying it and it was somewhere, I mean once you’re retired you look forward to going to 
certain places, and that’s what I did. I enjoyed it." (159) 
 
 Impact  
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The men discussed how the programme had impacted upon their quality of life, fitness levels, physical and mental 
health.  Men reported better improved fitness, ability to engage in everyday physical tasks without struggling as 
much as before and an improved mental health. 
  
 "I have to say the, the programme; the PANTERA programme’s transformed my life" (4 42) 
 
 " I know I’d, you know, I’d, I’d wrote some things down as we started the course about losing weight, getting 
fitter and that and so I were able to, and that’s what happened, you know, lost my weight." (202) 
 
Discussion 
The PANTERA trial is the first study of this magnitude to report the feasibility of aerobic ET as primary therapy for 
men with localised prostate cancer with retention of men randomised to ET extending to 12 months. Our study 
demonstrated good feasibility and acceptability in terms of recruitment, retention, sustained behaviour change and 
adherence with few adverse events and important impacts on clinically relevant outcomes in this population of men 
with localised disease. 
 
Observational data has suggested that physical activity could improve prostate cancer–specific mortality and overall 
mortality.8,9 Few clinical studies to date have evaluated the potential of ET as direct anti-cancer treatments in men 
with prostate cancer. A small single centre RCT of 26 men with localised disease recently reported feasibility 
outcomes from a combined lifestyle intervention of exercise and whole-grain rye diet supplementation.27 Over a six 
month intervention, the authors reported  a median level of 91 min/week of vigorous activity for the first 3 months 
and 66 min/week for the last 3 months from heart rate monitor recordings. It is important to note this study 
reported an adverse ratio of prostate cancer progression of 3 vs 0 men from the intervention group vs controls 
during the trial. Further this study retained less than 75% of its cohort, excluded men with PSA above 10 and also 
those with moderate or severe co-morbidity. The present study performed better in terms of trial retention, 
objectively recorded exercise behaviour,  had much more inclusive enrolment criteria (see Table 1) and over a 12 
month period, three men progressed to radical treatment: only one doing so from the ET group after discontinuing 
with exercise very early in the programme (i.e. after just one session).     
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The mechanisms whereby aerobic exercise reduces PCa progression are not clear: several pathways around how 
exercise might interact with the tumour microenvironment have been covered in a recent review.28 Nevertheless, 
the exact ‘dose’ of exercise required to achieve benefit is uncertain. Pilot 'lifestyle interventions' have been 
attempted but focused almost exclusively on strict dietary modification i.e. to veganism, without data on exercise 
dose/adherence.11 In contrast, we have used a specific and pre-specified target exercise intensity, supported by 
regular supervision and goal-setting13: the majority of men were able to either reach or indeed exceed such a 
threshold. Future large-scale trials are required to establish the dose-response curve and relationship between 
aerobic exercise and progression of localised prostate cancer.  Encouraging data from a small single centre RCT in 
men with biochemical recurrence following radical prostatectomy has reported improvements in fitness levels 
correlated with increasing PSA doubling time (n=12 completing training).29 We saw no impact on PSA over our 12 
month follow-up, but a longer follow-up could elucidate biomarker responses associated with cancer progression 
using ET as prescribed and delivered in PANTERA.  
 
The matter of acceptability of ET within active surveillance should be mentioned. Although self-empowerment has 
received much attention in cancer management in recent years, most of the effort and literature revolves around 
survivorship or self-empowerment after definitive management. Men with prostate cancer often describe low level 
of empowerment. Given the controversy around the risks and benefits of invasive therapies for localised prostate 
cancer, particularly in men considered to be at low risk of progression and considering the potential benefit 
suggested in reducing disease progression and mortality from observational studies, there is a real imperative to 
provide prospective evidence for such a management strategy - qualitative evaluation within this study found 
support from participants for continuing exercise prescription and longer follow-up (see online appendix 1). 
 
One of the commonest causes of death in men with prostate cancer is cardiovascular disease. Indeed, as 
demonstrated in the largest RCT thus far comparing treatment options, men with localised prostate cancer are nine 
times more likely to die of other causes rather than prostate cancer - CVD mortality being nearly three times more 
likely.1 As such men have a diagnosis of cancer, in the absence of autopsy data or central review of cause of death 
that the quoted rates are an underestimate in clinical practice. Physical activity is associated with reduced risk of 
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cardiovascular mortality in the general population as well as a reduction in the incident risk of other common 
cancers.12 We also found the ET impacted important markers of cardiovascular health i.e. both systolic and diastolic 
blood pressure in our study cohort. Whilst these are not cancer-specific, these represent clinically relevant changes26 
in important health outcomes in elderly men. The cardio-protective value of ET as a pre-cursor to conventional 
cardio-toxic prostate cancer treatments such as ADT30 is something of real clinical and health-economic interest in 
the management to prostate cancer survivors.  
 
Estimated costs of ET per-man in the PANTERA study would be £855 p.a. inclusive of specialist supervision, 
behaviour change, access to a community exercise facility and four progress/progression assessments per year. This 
cost figure does not take into consideration any health economic benefits from the ET such as fewer invasive cancer 
treatments, the cost to the health service of treating adverse effects of those treatments or reduction in risk of new 
co-morbidities associated with age.  ET also provided qualitative evidence about improved feelings of wellbeing 
which is supported by data from EQ5D assessments reporting improved quality of life. This is consistent with trials 
designed to improve cancer-specific quality of life in men with advanced disease.10 This is in stark contrast to 
conventional invasive approaches to localised disease management which have well established adverse effects on 
sexual, urinary and anorectal function.6 Therefore, developing ET as a novel primary treatment option for prostate 
cancer could fundamentally change the way the disease is managed and offer cancer specific and other health 
advantages.   
 
There are limitations to the present study that should be noted. Follow-up will likely need to be much longer in our 
definitive trial, extended to at least 3-5 years to provide sufficient time to detect changes in progression to invasive 
treatment endpoints.  No blinding was used in this phase II trial, so preliminary effects on subjective outcomes need 
to be interpreted with caution. More acceptable methods of collecting dietary confounders will need to be included 
in subsequent studies (e.g. three day diet diaries), given the food frequency questionnaire was poorly completed in 
our present cohort. Mechanistic data would be helpful in interpreting progression free survival data in the 
subsequent study: this will likely have to extend beyond typical kallikrein markers and could include immunological, 
metabolic and inflammation markers as well as circulating tumour cell profiles. Whilst the study was open to men 
with PSA over 10 ng.ml-1 and Gleason score above 6, the majority of recruits had a PSA of less than 10 ng.ml-1 and 
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Gleason score 3+3. Strategies to recruit men with intermediate risk disease could be developed to inform our 
definitive trial. The inclusion of exercise advice in the usual care arm could be a potential confounder in determining 
the true impact of a supervised exercise intervention. Nevertheless, given the observational evidence supporting the 
benefits of exercise in such an age cohort as well as the predominantly sedentary nature of the men recruited, 
providing no exercise guidelines was seen as unethical in this group. In any case, the provision of such guidance to 
the usual care group could have the effect of reducing the differences in study outcomes between the groups, 
something that will need to be factored into any future definitive study. 
 
Conclusion 
The PANTERA study demonstrated encouraging feasibility and early signals on clinically relevant markers in men with 
prostate cancer as a result of ET. A multi-centre definitive clinical trial to establish clinical and cost effectiveness is 
now indicated before such interventions could be considered as part of management in clinical practice.   
Figure legends 
Figure 1. PANTERA trial CONSORT diagram 
Figure 2. Total exercise behaviour over 12 months in minutes for all 23 exercise training participants, with blue bars = 
supervised exercise and red bars = independent exercise. Dashed line = 75% adherence or 5850 minutes in total. 
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Table 1. Baseline characteristics of men enrolled in the PANTERA study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exercise training 
 (n=25) 
Usual care with advice 
 (n=25) 
Age (yrs)   
mean (SD) 
 
68 (6) 67 (9) 
BMI (kg.m2)   
mean (SD) 
 
26.7 (2.4) 27.7 (3.2) 
Stage (n)   
T1a  1 
T1c 14 17 
T2a 11 6 
T2b 
 
 1 
Gleason score (n)   
3+3 24 23 
3+4 
 
1 2 
PSA (ng.ml-1)   
median (range) 5.6 (12.3,1.2) 5.6 (15.3,1.4) 
   
Co-morbidities (n)   
CVD 19 12 
Joint / bone 26 7 
Metabolic  5 2 
GI 7 5 
Chronic pain 1 3 
Mental health  3 
Pulmonary  1 3 
Eye disorder 2  
Inner ear disorder 3  
Skin disorder 1  
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Table 2. Secondary outcomes from the trial. 
 
Data is from 46 men completing 12 months follow-up. * = mean difference between baseline and 12 months with 
95% confidence intervals.  £=Exercise behaviour measured by the Godin questionnaire, $= Quality of life measured 
by the EQ5D questionnaire. Submaximal fitness was measured by Bruce treadmill protocol, data is from 42 complete 
cases over the four trial assessments. 
 
Usual care with advice 
 
Resting Hr 
(b.m-1) 
Diastolic 
BP (mmHg) 
Systolic 
BP 
(mmHg) 
Sub-
maximal 
fitness (s) 
Body 
mass (kg) 
BMI 
(kg/m2) 
Physical 
activity£ 
Quality of 
life$ 
Baseline 
        Mean 66 77 139 525 81.1 26.7 14 71 
95% CI (59,73) (73,82) (132,146) (461,588) (77.4,84.9) (25.6,27.7) (10,18) (64,78) 
3 months         
Mean 62 76 136 580 80.9 26.7 18 76 
95% CI (56,69) (73,80) (130,143) (537,623) (77.1,84.7) (25.6,27.9) (15,22) (70,81) 
6 months         
Mean 59 76 134 581 80.4 26.6 21 77 
95% CI (54,64) (72,79) (128,140) (528,634) (76.9,83.9) (25.6,27.6) (16,27) (72,83) 
12 months  
  
 
    Mean 61 76 135 574 80.4 26.6 29 79 
95% CI (56,65) (72,79) (127,142) (523,625) (76.8,84.0) (25.5,27.7) (19,40) (73,85) 
         Change* -5 -1 -4 49 -0.7 -0.1 15 8 
 
(-11,-1) (-5,2) (-10,2) (18,81) (-2.2,0.7) (-0.5,0.5) (5,25) (1,16) 
         
Exercise training 
 
Resting Hr 
(b.m-1) 
Diastolic 
BP (mmHg) 
Systolic 
BP 
(mmHg) 
Sub-
maximal 
fitness (s) 
Body 
mass (kg) 
BMI 
(kg/m2) 
Physical 
activity£ 
Quality of 
life$ 
Baseline 
        Mean 68 82 145 470 84.5 27.7 23 71 
95% CI (62,74) (79,85) (138,152) (395,544) (80.7,88.3) (26.4,29.1) (16,31) (64,79) 
3 months         
Mean 64 77 136 569 84.4 27.7 35 76 
95% CI  (59,69) (74,80) (129,142) (508,630) (80.3,88.4) (26.2,29.1) (19,50) (70,82) 
6 months 
   
 
    Mean 64 76 133 603 83.4 27.4 37 79 
95% CI (59,68) (73,79) (126,139) (545,662) (79.9,87.4) (26.2,28.7) (29,45) (74,83) 
12 months  
  
 
    Mean 62 74 132 641 82.5 27.1 43 84 
95% CI (58,66) (71,77) (125,139) (579,703) (78.7,86.3) (25.7,28.5) (33,53) (80,87) 
         Change* -6 -8 -13 171 -2.0 -0.6 20 13 
 (-10,-3) (-12,-5) (-19,-7) (124,219) (-2.9,-1.1) (-0.9,-0.4) (12,27) (7,18) 
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Table 3. Safety and other biomarkers from baseline to 12 months of follow-up 
PSA = prostate specific antigen, ST = serum testosterone, SHBG = sex hormone binding globulin, FAI = free androgen 
index, LDL = low density lipoprotein, HDL = high density lipoprotein, Total C = total cholesterol, TRIGs = triglycerides, 
HbA1c = glycated haemoglobin.  *mean change between baseline and 12 months of follow-up. Data is from 46 men 
completing 12 months follow-up. 
 
 
 
 
 
Usual care with advice 
 
PSA 
(ng/ml) 
ST 
(nmol/L) 
SHBG 
(nmol/L) FAI 
LDL 
(mmol/L) 
HDL 
(mmol/L) 
Total C 
(mmol/L) 
TRIGs 
(mmol/L) 
HbA1c 
(mmol/mol) 
Baseline 
         Mean 5.8 18.0 51.4 34.1 3.1 1.5 4.8 1.1 37.8 
95% CI (4.7,6.9) (15.2,20.8) (45.5,57.4) (30.0,38.1) (2.5,3.6) (1.3,1.6) (4.2,5.4) (0.9,1.3) (35.4,40.3) 
3 months          
Mean 5.6 16.9 55.2 31.7 2.9 1.5 4.9 1.0 37.0 
95% CI (4.6,6.6) (14.3,19.5) (46.9,63.5) (27.8,35.6) (2.4,3.4) (1.4,1.7) (4.3,5.4) (0.8,1.2) (34.9,39.1) 
6 months          
Mean 5.9 18.5 57.2 34.1 2.8 1.5 4.9 1.2 37.2 
95% CI (4.7,7.1) (16.1,21.0) (48.8,65.6) (29.6,38.7) (2.4,3.3) (1.3,1.7) (4.3,5.4) (0.9,1.5) (34.8,39.7) 
12 months          
Mean 5.7 18.1 56.5 31.4 2.9 1.5 4.9 1.1 36.4 
95% CI (4.5,6.9) (15.7,20.5) (49.7,63.3) (27.6,35.1) (2.4,3.3) (1.4,1.7) (4.4,5.4) (0.9,1.2) (34.9,38.0) 
 
         
Change* -0.1 0.1 5.1 -2.7 -0.2 0.0 0.1 0.0 -1.4 
 
(-1.0,0.7) (-1.7,1.8) (1.8,8.3) (-5.8,0.4) (-0.4,0.0) (0.0,0.1) (-0.2,0.3) (-0.2,0.2) (-3.0,0.2) 
Exercise training 
 
PSA 
(ng/ml) 
ST 
(nmol/L) 
SHBG 
(nmol/L) FAI 
LDL 
(mmol/L) 
HDL 
(mmol/L) 
Total C 
(mmol/L) 
TRIGs 
(mmol/L) 
HbA1c 
(mmol/mol) 
Baseline 
         Mean 6.4 14.3 44.2 33.2 2.6 1.4 4.5 1.3 40.9 
95% CI (5.1, 7.7) (12.3,16.4) (37.6,50.8) (29.1,37.3) (2.2,3.0) (1.2,1.5) (4.0,5.0) (1.0,1.6) (36.6,45.2) 
3 months          
Mean 6.3 14.5 46.2 31.3 2.5 1.4 4.4 1.3 40.4 
95% CI (5.1,7.5) (12.6,16.4) (38.2,54.3) (26.8,35.8) (2.0,2.9) (1.2,1.5) (3.9,4.9) (1.0,1.7) (36.2,44.6) 
6 months          
Mean 6.1 13.9 46.0 32.0 2.5 1.3 4.4 1.3 38.8 
95% CI (4.9,7.3) (12.1,15.7) (37.8,54.2) (27.7,36.4) (2.1,2.9) (1.2,1.5) (4.0,4.8) (1.0,1.5) (34.8,42.8) 
12 months          
Mean 6.4 14.2 48.7 31.0 2.3 1.4 4.3 1.3 41.8 
95% CI (5.0,7.9) (12.2,16.2) (40.2,57.3) (27.1,35.0) (1.9,2.7) (1.2,1.5) (3.9,4.7) (1.0,1.7) (36.0, 47.6) 
 
         
Change* 0.0 -0.1 4.5 -2.2 -0.3 0.0 -0.2 0.0 0.9 
 (-0.6,0.7) (-1.6,1.3) (1.2,7.8) (-5.3,1.0) (-0.5,-0.1) (-0.1,0.1) (-0.5,0.0) (-0.2,0.3) (-2.2,4.0) 
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Table 4. PANTERA qualitative feedback organised into superordinate and subordinate themes will illustrative quotes. 
 
Superordinate themes Subordinate themes  Selected illustrative quotes  
 
1. Motivations for 
participation in the 
trial 
1.1 Management of prostate 
cancer 
"Well he told me I’d got this stage one prostate 
cancer, and that by doing exercises it could help 
reduce it, reduce the PSA, so that’s why I was involved 
with it." 159 
 1.2 To benefit others in the future “Well, I do believe that, you know, that people should, 
should do trials and was quite willing to do trials if it’s 
going to help myself and mainly if it’s going to help 
others in the future.” 469 
 1.3 Improvement of fitness 
 
" I wanted to get fit, because I was very unfit." 205 
 1.4 Initial concerns  "It was something, I hadn’t gone to a gym before, so I 
got a bit worried at the first couple of sessions, but I 
was all right then." 159 
2 Trial design 2.1 Delivery "Actually it all right, it went very quickly. And had it 
said do another six months or another year I’d have 
done it. Yeah, because I was enjoying it and it was 
somewhere, I mean once you’re retired you look 
forward to going to certain places, and that’s what I 
did. I enjoyed it."159 
 2.2 Intensity "No, it was about right. I mean I did start doing a bit 
more as I went on, and obviously you improve over 
that period of time anyway so you go a bit faster or 
work a bit harder. So yeah, I found it quite within my 
capabilities."310 
 2.3 Monitoring "Yeah, my generation are being left behind with 
technology basically. And even if it’s just a simple 
question of pressing the right button, you don’t 
always find it straightaway. But essentially I mean I 
would say I was 90-95% of the time it’s fine. " 248 
3. Adherence  3.1 Supervision with integrated 
behavioural support  
"If I’d been left unsupervised I probably would have 
kept on the same levels of machinery; whereas he 
urged us to go forward a bit higher each time. And we 
got on quite well, he was very good."159 
 3.2 Perceived benefits of peer 
support 
"The, thought that other people on the group were 
probably going to be there and that I was missing 
out." 442 
 3.3 Psychological and physical 
benefits 
"Yeah I did, I think it does help with mental issues 
anyway. People with depression and things like that I 
think it helps. And I think a lot of people were cheesed 
off with it, with prostate cancer." 205 
 3.4 Flexibility "Yeah, yeah and like I said if anything else happened 
I’d, there were always alternative times, so if ought 
happened in the morning and I weren’t able to go, 
there was always another, he’d always got another 
alternative for you.." 202 
4.Impact 4.1 Quality of life There’s a few, I mean obviously physically I think I’m 
fitter than I’ve ever "been! Um, so I think it’s been,  
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you know, health, health wise in that just feeling 
better and feeling fitter  has been good and I think 
there is a bit of a, it’s quite supportive to go to 
something with other people who are, who have got 
the same issues." 447 
 4.2 Health improvements  " I know I’d, you know, I’d, I’d wrote some things 
down as we started the course about losing weight, 
getting fitter and that and so I were able to, and 
that’s what happened, you know, lost my weight." 
202 
 4.3  Confidence "To be honest what the gym did, it gave me, I mean I 
was unfit but it gave me the confidence to do it." 205 
 4.4 Improvement in exercise 
levels and behaviour  
"I have joined a gym; I go three times a week now." 
159 
 
 
 
 
